Amalgamated Bank’s Precision BioSciences DTIL Stock Holding History

Amalgamated Bank’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-275	Closed	-$25K	–	3079
2022 Q1	$25K	Buy	+275	New	+$37.4K	﹤0.01%	2734

Other funds holding DTIL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Amalgamated Bank's DTIL Position: Q2 2022 in Review

Amalgamated Bank sold out of Precision BioSciences (DTIL) in Q2 2022, closing a stake of 275 shares — an estimated $25K sold.

Amalgamated Bank first reported a position in DTIL in Q1 2022 and held it in 1 quarter. The position peaked at $25K in Q1 2022. 119 funds tracked by Wall St. Rank hold DTIL as of Q2 2022.

Amalgamated Bank reported no remaining Precision BioSciences position as of Q2 2022 after selling out during the quarter.
Amalgamated Bank sold 275 Precision BioSciences shares in Q2 2022, an estimated $25K.
Amalgamated Bank first reported a position in Precision BioSciences in Q1 2022 and held it in 1 quarter.
Amalgamated Bank's Precision BioSciences position peaked at $25K in Q1 2022.
119 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.